Boehringer Ingelheim Corporate News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Boehringer Ingelheim fosters cooperation with innovative partners
Digital transformation: Boehringer Ingelheim fosters cooperation with innovative partnersDigital technologies can contribute to improved monitoring, more rapid diagnosis, and more successful treatmentPilot project with Belgian start-up SoundTalks facilitates disease prevention among farm animals Open innovation online portal promotes collaboration with external partners in research and development (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 14, 2019 Category: Research Source Type: news

Accelerator_program_mmh
Boehringer Ingelheim announces finalists of the Making More Health Accelerator ProgramBoehringer Ingelheim to support scale up of two projects of its Making More Health (MMH) Accelerator Program.The Accelerator Program aims to help early stage enterprises develop sustainable care delivery models. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - May 2, 2019 Category: Research Source Type: news

annual_results_press_conference_2019
Financial year 2018: Boehringer Ingelheim grows and invests Well-filled research pipeline in oncology, fibrotic diseases, immunology and metabolic diseasesOperating growth outpaces the market in all businessesTechnical integration of the animal health business acquired in 2017 successfully completed (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 16, 2019 Category: Research Source Type: news

Boehringer Ingelheim acquires a stake in SoundTalks
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme Boehringer Ingelheim plans a pilot programme using the innovative SoundTalksTM system in select pig barnsThe goal is to harness the power of digital innovation and technological change to detect possible respiratory distress in swine quickly (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 15, 2019 Category: Research Source Type: news

Real-world-study-comparing-NOACs-in-AF-patients
Independent large real-world study comparing NOACs in AF-patientsA recently published large retrospective comparative study investigated stroke, bleeding and mortality risks in older US Medicare patients treated with commonly marketed oral anticoagulants for non-valvular atrial fibrillation1 Results of the real-world study showed that Pradaxa ® (dabigatran etexilate) was associated with a more favourable benefit-risk profile in comparison to both warfarin and rivaroxaban1Data from an earlier FDA-funded Medicare study published in 2015, which investigated cardiovascular, bleeding and mortality risks among patients treate...
Source: Boehringer Ingelheim Corporate News - April 15, 2019 Category: Research Source Type: news

effectiveness-analysis-in-diabetic-kidney-disease-and-type-2-diabetes
New post-hoc analysis of EMPA-REG OUTCOME ® examined cost-effectiveness of empagliflozin versus standard of care in a subgroup of people with type 2 diabetes and diabetic kidney disease Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1 Cost effective analysis used modeling and simulations based on subgroup data from EMPA-REG OUTCOME ® to predict clinical events and estimated costs for people with type 2 diabetes and diabetic kidney disea...
Source: Boehringer Ingelheim Corporate News - April 14, 2019 Category: Research Source Type: news

Celebrating 20 years of Metacam for cattle
Boehringer Ingelheim celebrates 20 years of Metacam ® for cattle2019 marks the anniversary of Metacam ® (meloxicam) for cattleOriginally licenced for dogs, Metacam ®can be used in other species to treat inflammatory and painful conditionsBoehringer Ingelheim celebrates this 20-year milestone since pioneering meloxicam for use in both humans and animals (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2019 Category: Research Source Type: news

Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and DortmundEuropean launches of next-generation inhaler kicked off (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 11, 2019 Category: Research Source Type: news

Arti-cell Forte stem cell-based veterinary product
Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicineEuropean Commission has granted marketing authorisation for the first stem cell-based product in animal healthArti-Cell ® Forte is a unique ready-to-use solution for the treatment of equine lamenessThe partnership of Boehringer Ingelheim and GST proves its commitment to bring highly innovative therapeutics for horses to customers (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 7, 2019 Category: Research Source Type: news

‘uniqueness’ by championing both human and animal health
Boehringer Ingelheim celebrates its ‘uniqueness’ by championing both human and animal health in new campaign Boehringer Ingelheim changes perception due to its dedication to human and animal health“A Unique Bond” explores stories of the positive impact animals can have on patient’s lives Launched in 28 countries, the company affirms its dedication to both human and animal health with local initiatives (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 3, 2019 Category: Research Source Type: news

Positivity... just a paw away
Positivity … just a paw awayOwners claim that their pet has a strong positive impact on their daily lives.1 According to experts, “pets benefit the lives of their owners, both psychologically and physically”.2 Acknowledging this, Boehringer Ingelheim launches global initiatives to improve the positivity of their employees, patients and animals alike. (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 3, 2019 Category: Research Source Type: news

Why we may be more like our pets than we think
Like their owners, pets are living longer1 and are prone to conditions such as cancer and obesity.2,3,4Recent data exploring the human-animal connection shows that pets are integral to improving our quality of life.5A global campaign reveals the remarkable bond between people and animals, and how pets can help provide support through illness as well as recovery.6 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 2, 2019 Category: Research Source Type: news

Launch of BVDzero scholarship for veterinary students
Boehringer Ingelheim launches BVDzero scholarship for veterinary students globallyBoehringer Ingelheim grants a total BVDzero scholarship of 10,000 euro to top 10 students worldwideThe company aims to increase bovine viral diarrhea (BVD) awareness among veterinary studentsThis initiative is implemented in collaboration with the World Association for Buiatrics, as an incentive to participate in the World Buiatrics Congress 2020 in Madrid (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 29, 2019 Category: Research Source Type: news

Acquisition Saint-Herblon site and Coophavet brand
Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production siteThe acquisition includes the Saint-Herblon production site and the Coophavet brandThe sale is part of the Boehringer Ingelheim ’s strategic refocusing on advanced and preventive animal healthcare (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 29, 2019 Category: Research Source Type: news

Acquisition of novel oncology delivery technology
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD TherapeuticsNew molecular platform to access intracellular targets across a broad range of tumor cell typesOpens up new range of therapeutic opportunities for difficult-to-treat cancers (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 29, 2019 Category: Research Source Type: news